Dopamine agonist therapy in early Parkinson's disease
- 23 April 2008
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (1) , CD006564
Abstract
Background Dopamine agonists are being used increasingly as first line treatment for Parkinson's disease, but there remains uncertainty about their clinical and cost‐effectiveness relative to levodopa. Objectives This meta‐analysis aims to quantify more reliably the benefits and risks of dopamine agonists compared to placebo or levodopa in early Parkinson's disease. Search methods We searched CENTRAL (The Cochrane Library), MEDLINE, EMBASE, PubMed, LILACS and Web of Science, plus major journals in the field, abstract books, conference proceedings and reference lists of retrieved publications. Selection criteria Randomised trials comparing an orally administered dopamine agonist (with or without levodopa) versus placebo or levodopa or both placebo and levodopa in participants with early Parkinson's disease. Data collection and analysis Two authors independently extracted data on clinician‐rated disability, motor complications, other side‐effects, treatment concordance, levodopa dose and mortality. Main results Twenty‐nine eligible trials, involving 5247 participants, were identified. Participants randomised to a dopamine agonist were less likely to develop dyskinesia (odds ratio (OR) 0.51, 95% confidence interval (CI) 0.43 to 0.59; P < 0.00001), dystonia (OR 0.64, 95% CI 0.51 to 0.81; P = 0.0002) and motor fluctuations (OR 0.75, 95% CI 0.63 to 0.90; P = 0.002) than levodopa‐treated participants. However, various 'non‐motor' side‐effects, including oedema (OR 3.68, 95% CI 2.62 to 5.18; P < 0.00001), somnolence (OR 1.49, 95% CI 1.12 to 2.00; P = 0.007), constipation (OR 1.59, 95% CI 1.11 to 2.28; P = 0.01), dizziness (OR 1.45, 95% CI 1.09 to 1.92; P = 0.01), hallucinations (OR 1.69, 95% CI 1.13 to 2.52; P = 0.01) and nausea (OR 1.32, 95% CI 1.05 to 1.66; P = 0.02) were all increased in agonist‐treated participants (compared with levodopa‐treated participants). Agonist‐treated participants were also significantly more likely to discontinue treatment due to adverse events (OR 2.49, 95% CI 2.08 to 2.98; P < 0.00001). Finally symptomatic control of Parkinson's disease was better with levodopa than with agonists, but data were reported too inconsistently and incompletely to meta‐analyse. Authors' conclusions This meta‐analysis confirms that motor complications are reduced with dopamine agonists compared to levodopa, but also establishes that other important side‐effects are increased and symptom control is poorer with agonists. Larger, long‐term comparative trials assessing patient‐rated quality of life are needed to assess more reliably the balance of benefits and risks of dopamine agonists compared to levodopa.Keywords
This publication has 44 references indexed in Scilit:
- Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET studyMovement Disorders, 2006
- Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled studyMovement Disorders, 2003
- Factors impacting on quality of life in Parkinson's disease: Results from an international surveyMovement Disorders, 2002
- Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications?European Journal of Neurology, 1998
- Early Treatment of Parkinson??s Disease with Cabergoline Delays the Onset of Motor ComplicationsDrugs, 1998
- Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyJournal of Neural Transmission, 1996
- Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.BMJ, 1993
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug ProjectNew England Journal of Medicine, 1980